A retrospective real-world experience of immunotherapy in patients with extensive stage small-cell lung cancer.

ABSTRACT:

Background

The treatment of extensive stage small-cell lung cancer (ES-SCLC) has only made modest progress in the past decade, with two immune checkpoint inhibitors (ICIs), atezolizumab and durvalumab, approved for the treatment of SCLC by January 2022. However, currently, there is limited real-world data on ES-SCLC patients received immunotherapy.

Methods

We retrospectively collected and analyzed the demographic and treatment data of ES-SCLC patients at the First Affiliated Hospital of Guangzhou Medical University from January 2017 to January 2022. Survival and prognosis information was obtained through follow-up.

Results

A total of 353 ES-SCLC patients were included, of which 165 received immunotherapy combined with chemotherapy as the first-line (FL) treatment (che

SUBMITTER: Qiu G 

PROVIDER: S-EPMC10417203 | biostudies-literature | 2023 Jul

REPOSITORIES: biostudies-literature